Zoetis Inc (ZTS.N)
29.77USD
10:56am EDT
$-0.04 (-0.13%)
$29.81
$29.95
$30.00
$29.46
318,472
1,679,969
$35.40
$28.97
About
Overall
| Beta: | -- |
| Market Cap (Mil.): | $14,905.00 |
| Shares Outstanding (Mil.): | 500.00 |
| Dividend: | 0.06 |
| Yield (%): | 0.87 |
Financials
| ZTS.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 32.06 | 37.93 | 37.76 |
| EPS (TTM): | 0.93 | -- | -- |
| ROI: | 9.35 | 19.48 | 18.76 |
| ROE: | 20.03 | 20.17 | 19.59 |
Pfizer says shareholders snap up remaining Zoetis shares
- Pfizer Inc on Monday said it would complete the spinoff of its Zoetis Inc animal health business after investors offered to trade their Pfizer shares for the company's remaining majority stake in the unit.
UPDATE 2-Pfizer says shareholders snap up remaining Zoetis shares
June 24 - Pfizer Inc on Monday said it would complete the spinoff of its Zoetis Inc animal health business after investors offered to trade their Pfizer shares for the company's remaining majority stake in the unit.
Pfizer says shareholders snap up remaining Zoetis shares
June 24 - Pfizer Inc said on Monday that enough Pfizer shareholders offered to trade their shares for stock in Pfizer's majority owned Zoetis Inc animal health business to allow Pfizer to complete its spinoff of the unit.
Pfizer to spin off Zoetis stake to shareholders
- Pfizer Inc said on Wednesday it will spin off its majority stake in animal health business Zoetis Inc to shareholders by allowing them to swap Pfizer stock for Zoetis shares at a 7 percent discount.
UPDATE 2-Pfizer to spin off Zoetis stake to shareholders
May 22 - Pfizer Inc said on Wednesday it will spin off its majority stake in animal health business Zoetis Inc to shareholders by allowing them to swap Pfizer stock for Zoetis shares at a 7 percent discount.
BRIEF-Pfizer up in premarket after plans to unwind remaining majority stake in Zoetis
NEW YORK, May 22 - Pfizer Inc : * Up 2.2 percent to $29.40 in premarket after plans to unwind remaining majority stake in Zoetis
Strong pet product sales help Zoetis top estimates
- Zoetis Inc , formerly the animal health subsidiary of U.S. pharmaceuticals giant Pfizer Inc , posted a stronger-than-expected quarterly profit, driven by growth in sales of pet products in the United States.
UPDATE 2-Strong pet product sales help Zoetis top estimates
April 30 - Zoetis Inc, formerly the animal health subsidiary of U.S. pharmaceuticals giant Pfizer Inc , posted a stronger-than-expected quarterly profit, driven by growth in sales of pet products in the United States.
Zoetis profit beats Street on strong pet product sales
- Zoetis Inc , formerly the animal health subsidiary of U.S. pharmaceuticals giant Pfizer Inc , posted a better-than-expected quarterly profit, driven by strong growth in sales of pet products in the United States.
Zoetis profit beats Street on strong pet product sales
April 30 - Zoetis Inc, formerly the animal health subsidiary of U.S. pharmaceuticals giant Pfizer Inc , posted a better-than-expected quarterly profit, driven by strong growth in sales of pet products in the United States.
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$115.00
|
|
Provider: Wright Reports
|
$368.00
|
|
Provider: Zacks Investment Research Inc.
|
$12.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

